Marker Therapeutics Inc (MRKR) USD0.001
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The Company has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. The Company is advancing two pipelines of product candidates as part of its MultiTAA-specific T cell program: the autologous T cells for the treatment of lymphoma, multiple myeloma (MM) and selected solid tumors, and the allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.